Etoposide – Uses, Dosage, Side Effects, Interaction Etoposide is a semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum. Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04). A phosphate salt of a semisynthetic derivative of podophyllotoxin. Etoposide binds to the enzyme topoisomerase II, inducing double-strand DNA breaks, inhibiting DNA repair, and resulting in decreased DNA synthesis and tumor cell proliferation. Cells in the S and G2 phases of the cell cycle are most sensitive to this agent. (NCI04) Etoposide is a beta-D-glucoside, a furonaphthodioxole, and an organic heterotetracyclic compound. It has a role as an antineoplastic agent and a DNA synthesis inhibitor. It is functionally related to a podophyllotoxin and a 4′-demethylepipodophyllotoxin. Etoposide Toniribate is a prodrug of etoposide, a semisynthetic derivative of podophyllotoxin extracted from the mandrake root Podophyllum peltatum, with potential antineoplastic activity. Upon intravenous administration of etoposide toniribate, etoposide is released after enzymatic cleavage of CAP7.1 by specific carboxylesterases (CE) 1 and 2, which are upregulated in certain tumor cell types. Etoposide acts primarily in the G2 and S phases of the cell cycle. This drug binds to and inhibits topoisomerase II, an enzyme elevated in tumor cells. This results in the accumulation of double-strand DNA breaks, the inhibition of DNA replication and transcription, and the induction of apoptotic cell death. The tumor-specific activation of etoposide increases its efficacy while lowering its systemic toxicity. Etoposide Phosphate is a phosphate salt of a semisynthetic derivative of podophyllotoxin. Etoposide binds to the enzyme topoisomerase II, inducing double-strand DNA breaks, inhibiting DNA repair, and resulting in decreased DNA synthesis and tumor cell proliferation. Cells in the S and G2 phases of the cell cycle are most sensitive to this agent. (NCI04) Mechanism of Action Etoposide inhibits DNA topoisomerase II, thereby inhibiting DNA re-ligation. This causes critical errors in DNA synthesis at the premitotic stage of cell division and can lead to apoptosis of the cancer cell. Etoposide is cell cycle-dependent and phase-specific, affecting mainly the S and G2 phases of cell division. Inhibition of the topoisomerase II alpha isoform results in the anti-tumor activity of etoposide. The drug is also capable of inhibiting the beta isoform but inhibition of this target is not associated with the anti-tumor activity. It is instead associated with the carcinogenic effect. or Etoposide has been shown to arrest metaphase in chick fibroblasts, but its principal effect in mammalian cells appears to be in the G2 phase. At etoposide concentrations of 0.3-10 ug/ml in vitro, cells are inhibited from entering prophase; at concentrations of 10 ug/ml or higher, lysis of cells entering mitosis occurs. Etoposide does not inhibit microtubule assembly. Etoposide has been shown to induce single-stranded DNA breaks in HeLa cells and in murine leukemia L1210 cells in vitro; the drug also induces double-stranded DNA breaks and DNA-protein crosslinks in L1210 cells. Etoposide-induced DNA damage appears to correlate well with the cytotoxicity of the drug. Etoposide appears to induce single-stranded DNA breaks indirectly, possibly through endonuclease activation, inhibition of intranuclear type II topoisomerase, or formation of a free-radical metabolite via an enzymatic reaction involving the hydroxyl group at the C-4′ position of the E ring. Etoposide also reversibly inhibits the facilitated diffusion of nucleosides into HeLa cells in a concentration-dependent manner in vitro. Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby ultimately inhibiting DNA synthesis. Etoposide is cell cycle-dependent and phase-specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 µg/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 µg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals. A prodrug of etoposide, a semisynthetic derivative of podophyllotoxin extracted from the mandrake root Podophyllum peltatum, with potential antineoplastic activity. Upon intravenous administration of etoposide toniribate, etoposide is released after enzymatic cleavage of CAP7.1 by specific carboxylesterases (CE) 1 and 2, which are upregulated in certain tumor cell types. Etoposide acts primarily in the G2 and S phases of the cell cycle. This drug binds to and inhibits topoisomerase II, an enzyme elevated in tumor cells. This results in the accumulation of double-strand DNA breaks, the inhibition of DNA replication and transcription, and the induction of apoptotic cell death. The tumor-specific activation of etoposide increases its efficacy while lowering its systemic toxicity. Indications For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first-line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme. Use in Cancer Bicalutamide is approved to treat: Prostate cancer that has metastasized (spread to other parts of the body). It is used with a type of drug called a luteinizing hormone-releasing hormone agonist. Bicalutamide is also being studied in the treatment of other types of cancer. Contraindications a bad infection low amount of albumin proteins in the blood excess body acid decreased function of bone marrow anemia decreased blood platelets a significant decrease in certain blood clotting cells called platelets low levels of white blood cells low levels of a type of white blood cell called neutrophils bleeding a type of inflammation of the lung called interstitial pneumonitis a condition where there is a formation of fibrous tissue in the lung called pulmonary fibrosis damage to the liver and inflammation pregnancy a patient who is producing milk and breastfeeding moderate to severe kidney impairment a significant drop in a certain type of white blood cell called a neutrophil Dosage Strengths: 20 mg/mL; 50 mg Testicular Cancer In combination with other approved chemotherapeutic agents 50 to 100 mg/m2 IV over 30 to 60 minutes once a day on days 1 through 5 every 3 to 4 weeks to 100 mg/m2 IV over 30 to 60 minutes once a day on days 1, 3, and 5 every 3 to 4 weeks A longer duration of IV administration may be used if the volume of fluid to be infused is a concern. The dosage should be modified to consider the myelosuppressive effects of other drugs in the combination or the effects of prior x-ray therapy or chemotherapy which may have compromised bone marrow reserve. Small Cell Lung Cancer IV: In combination with other approved chemotherapeutic agents: 35 mg/m2 IV over 30 to 60 minutes once a day for 4 days to 50 mg/m2 IV over 30 to 60 minutes once a day for 5 days every 3 to 4 weeks Oral: In combination with other approved chemotherapeutic agents: The recommended dose is 2 times the IV dose rounded to the nearest 50 mg (i.e., 2 times 35 mg/m2 IV once a day for 4 days to 50 mg/m2 IV once a day for 5 days equaling 70 mg/m2 orally once a day for 4 days to 100 mg/m2 orally once a day for 5 days) A longer duration of IV administration may be used if the volume of fluid to be infused is a concern. The dosage should be modified to consider the myelosuppressive effects of other drugs in the combination or the effects of prior x-ray therapy or chemotherapy which may have compromised bone marrow reserve. Renal Dose Adjustments CrCl greater than 50 mL/min: Administer 100% of the normal dose CrCl 15 to 50 mL/min: Administer 75% of the normal dose CrCl less than 15 mL/min: Data not available Side Effects The Most Common nausea vomiting sores in the mouth and throat stomach pain diarrhea constipation loss of appetite or weight unusual tiredness or weakness pale skin fainting dizziness hair loss pain, burning, or tingling in the hands or feet eye pain vision problems rash hives itching difficulty breathing or swallowing fast, irregular, or pounding heartbeat seizures yellowing of the skin or eyes More Common sudden chest pain or discomfort, wheezing, dry cough or hack; easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin; vision problems; seizure (convulsions); liver problems–loss of appetite, stomach pain (upper right side), tiredness, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); low red blood cells (anemia)–pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or low white blood cell counts–fever, mouth sores, skin sores, sore throat, cough, trouble breathing. sores or white patches in or around your mouth, trouble swallowing or talking, dry mouth, bad breath, altered sense of taste; nausea, vomiting; or temporary hair loss. Rare appetite loss diarrhea nausea and vomiting temporary loss of hair dizziness or lightheadedness low blood pressure numbness or tingling in fingers and toes pain at the site of injection painful swallowing seizures signs of bleeding (e.g., bloody nose, blood in urine, coughing blood, cuts that don’t stop bleeding, unusual bleeding or bruising black or tarry stools, or blood in urine) signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools) skin rash or itching signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness) sores in the mouth or on the lips unusual tiredness or weakness signs of a serious allergic reaction (i.e., abdominal cramps, difficulty breathing, nausea and vomiting, sweating, fast heartbeat, or swelling of the face and throat) Drug Interaction DRUG INTERACTION Abametapir The serum concentration of Etoposide can be increased when it is combined with Abametapir. Abatacept The metabolism of Etoposide can be increased when combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Etoposide. Abemaciclib Abemaciclib may decrease the excretion rate of Etoposide which could result in a higher serum level. Abiraterone The serum concentration of Etoposide can be increased when it is combined with Abiraterone. Abrocitinib The serum concentration of Etoposide can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Etoposide can be decreased when combined with Acalabrutinib. Acenocoumarol The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Etoposide. Acetaminophen The metabolism of Etoposide can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Etoposide can be decreased when combined with Acetazolamide. Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Etoposide. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Etoposide. Acyclovir The metabolism of Acyclovir can be decreased when combined with Etoposide. Adalimumab The metabolism of Etoposide can be increased when combined with Adalimumab. Adenine The metabolism of Etoposide can be decreased when combined with Adenine. Adenovirus The risk or severity of infection can be increased when the Adenovirus type 7 vaccine live is combined with Etoposide. Afatinib The serum concentration of Etoposide can be increased when it is combined with Afatinib. Agomelatine The metabolism of Agomelatine can be decreased when combined with Etoposide. Albendazole The metabolism of Etoposide can be increased when combined with Albendazole. Aldesleukin The metabolism of Etoposide can be decreased when combined with Aldesleukin. Alectinib Alectinib may decrease the excretion rate of Etoposide which could result in a higher serum level. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Etoposide. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etoposide. Alfentanil The metabolism of Etoposide can be decreased when combined with Alfentanil. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Etoposide. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Etoposide. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Etoposide. Alosetron The metabolism of Etoposide can be decreased when combined with Alosetron. Alpelisib The metabolism of Etoposide can be increased when combined with Alpelisib. Alprazolam The metabolism of Alprazolam can be decreased when combined with Etoposide. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Etoposide. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Etoposide. Ambrisentan The metabolism of Etoposide can be decreased when combined with Ambrisentan. Aminoglutethimide The metabolism of Etoposide can be increased when combined with Aminoglutethimide. Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Etoposide. Aminophylline The metabolism of Aminophylline can be decreased when combined with Etoposide. Amiodarone The metabolism of Etoposide can be decreased when combined with Amiodarone. Amitriptyline The metabolism of Etoposide can be decreased when combined with Amitriptyline. Amobarbital The metabolism of Etoposide can be increased when combined with Amobarbital. Amprenavir The metabolism of Etoposide can be decreased when combined with Amprenavir. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Etoposide. Anagrelide The metabolism of Etoposide can be decreased when combined with Anagrelide. Anakinra The metabolism of Etoposide can be increased when combined with Anakinra. Anastrozole The risk or severity of cardiotoxicity can be increased when Etoposide is combined with Anastrozole. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Etoposide. Anifrolumab The risk or severity of adverse effects can be increased when Etoposide is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Etoposide. Anthrax immune The therapeutic efficacy of Anthrax immune globulin in humans can be decreased when used in combination with Etoposide. Anthrax vaccine The risk or severity of infection can be increased when the Anthrax vaccine is combined with Etoposide. antilymphocyte The risk or severity of adverse effects can be increased when Etoposide is combined with Antilymphocyte immunoglobulin (horse). Antipyrine The metabolism of Antipyrine can be decreased when combined with Etoposide. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Etoposide. Antithrombin The risk or severity of bleeding can be increased when Antithrombin III human is combined with Etoposide. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etoposide. Apalutamide The serum concentration of Etoposide can be decreased when it is combined with Apalutamide. Apixaban The metabolism of Etoposide can be decreased when combined with Apixaban. Apomorphine The metabolism of Etoposide can be decreased when combined with Apomorphine. Apremilast The metabolism of Etoposide can be increased when combined with Apremilast. Aprepitant The metabolism of Etoposide can be decreased when combined with Aprepitant. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Etoposide. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Etoposide. Aripiprazole The metabolism of Aripiprazole can be increased when combined with Etoposide. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Etoposide. Armodafinil The metabolism of Etoposide can be increased when combined with Armodafinil. Arsenic trioxide The serum concentration of Etoposide can be increased when it is combined with Arsenic trioxide. Artemether The metabolism of Etoposide can be decreased when combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Articaine. Asciminib The serum concentration of Etoposide can be increased when it is combined with Asciminib. Asenapine The metabolism of Asenapine can be decreased when combined with Etoposide. Astemizole The metabolism of Etoposide can be decreased when combined with Astemizole. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Etoposide. Asunaprevir The serum concentration of Etoposide can be increased when it is combined with Asunaprevir. Atazanavir The metabolism of Etoposide can be decreased when combined with Atazanavir. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Etoposide. Atovaquone The serum concentration of Etoposide can be increased when it is combined with Atovaquone. Avacopan The metabolism of Etoposide can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Etoposide. Avatrombopag Avatrombopag may decrease the excretion rate of Etoposide which could result in a higher serum level. Axitinib The metabolism of Axitinib can be decreased when combined with Etoposide. Azacitidine The risk or severity of adverse effects can be increased when Etoposide is combined with Azacitidine. Azathioprine The risk or severity of adverse effects can be increased when Etoposide is combined with Azathioprine. Azelastine The metabolism of Etoposide can be decreased when combined with Azelastine. Azithromycin The metabolism of Etoposide can be decreased when combined with Azithromycin. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Etoposide. BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Etoposide. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Etoposide. Baricitinib The risk or severity of adverse effects can be increased when Etoposide is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Etoposide. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Etoposide. Beclomethasone The metabolism of Etoposide can be increased when combined with Beclomethasone dipropionate. Belantamab The serum concentration of Etoposide can be increased when it is combined with Belantamab mafodotin. Belatacept The risk or severity of adverse effects can be increased when Etoposide is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Etoposide is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Etoposide is combined with Belinostat. Belumosudil The serum concentration of Etoposide can be increased when it is combined with Belumosudil. Belzutifan The serum concentration of Etoposide can be decreased when it is combined with Belzutifan. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Etoposide. Bendamustine The risk or severity of adverse effects can be increased when Etoposide is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Etoposide. Benzocaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Benzocaine. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Etoposide. Bosentan The metabolism of Etoposide can be increased when combined with Bosentan. Bosutinib The metabolism of Etoposide can be decreased when combined with Bosutinib. Brentuximab vedotin The metabolism of Etoposide can be decreased when combined with Brentuximab vedotin. Brigatinib Brigatinib may decrease the excretion rate of Etoposide which could result in a higher serum level. Brodalumab The risk or severity of adverse effects can be increased when Etoposide is combined with Brodalumab. Bromazepam The metabolism of Bromazepam can be decreased when combined with Etoposide. Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Etoposide. Budesonide The metabolism of Etoposide can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Bupivacaine. Buprenorphine The metabolism of Etoposide can be decreased when combined with Buprenorphine. Buspirone The metabolism of Etoposide can be decreased when combined with Buspirone. Busulfan The risk or severity of adverse effects can be increased when Etoposide is combined with Busulfan. Butacaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Butacaine. Butalbital The metabolism of Etoposide can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Butamben. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Etoposide. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Etoposide. Caffeine The metabolism of Etoposide can be decreased when combined with Caffeine. Calcitriol The metabolism of Etoposide can be increased when combined with Calcitriol. Canagliflozin The serum concentration of Etoposide can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Etoposide can be increased when combined with Canakinumab. Candicidin The metabolism of Etoposide can be decreased when combined with Candicidin. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Etoposide. Cannabidiol The metabolism of Etoposide can be decreased when combined with Cannabidiol. Capecitabine The risk or severity of adverse effects can be increased when Etoposide is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Etoposide. Capmatinib The serum concentration of Capmatinib can be decreased when it is combined with Etoposide. Capsaicin The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Capsaicin. Carbamazepine The metabolism of Etoposide can be increased when combined with Carbamazepine. Carboplatin The risk or severity of adverse effects can be increased when Etoposide is combined with Carboplatin. Carfilzomib The serum concentration of Etoposide can be increased when it is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Etoposide. Carvedilol The serum concentration of Etoposide can be increased when it is combined with Carvedilol. Cefradine The metabolism of Etoposide can be increased when combined with Cefradine. Cenobamate The serum concentration of Etoposide can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Etoposide can be decreased when combined with Cephalexin. Ceritinib The metabolism of Etoposide can be decreased when combined with Ceritinib. Cerivastatin The metabolism of Etoposide can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Etoposide can be increased when combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Etoposide. Chloramphenicol The metabolism of Etoposide can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Chloroprocaine. Chloroquine The metabolism of Etoposide can be decreased when combined with Chloroquine. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Etoposide. Chlorpheniramine The metabolism of Etoposide can be decreased when combined with Chlorpheniramine. Chlorpromazine The metabolism of Etoposide can be increased when combined with Chlorpromazine. Chlorzoxazone The metabolism of Etoposide can be decreased when combined with Chlorzoxazone. Cholesterol Cholesterol may increase the excretion rate of Etoposide which could result in a lower serum level and potentially a reduction in efficacy. Ciclesonide The risk or severity of adverse effects can be increased when Etoposide is combined with Ciclesonide. Cilostazol The metabolism of Cilostazol can be decreased when combined with Etoposide. Cimetidine The metabolism of Etoposide can be decreased when combined with Cimetidine. Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Etoposide. Cinchocaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Cinchocaine. Cinnarizine The metabolism of Etoposide can be decreased when combined with Cinnarizine. Cinoxacin The metabolism of Etoposide can be decreased when combined with Cinoxacin. Ciprofloxacin The metabolism of Etoposide can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Etoposide can be decreased when combined with Cisapride. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Etoposide. Citalopram The metabolism of Etoposide can be decreased when combined with Citalopram. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Etoposide. Clarithromycin The metabolism of Etoposide can be decreased when combined with Clarithromycin. Clevidipine The metabolism of Etoposide can be increased when combined with Clevidipine. Clindamycin The metabolism of Clindamycin can be increased when combined with Etoposide. Clobazam The metabolism of Etoposide can be increased when combined with Clobazam. Clobetasol propionate The metabolism of Etoposide can be increased when combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Etoposide. Clofazimine The serum concentration of Etoposide can be increased when it is combined with Clofazimine. Clofibrate The metabolism of Etoposide can be increased when combined with Clofibrate. Clomifene The serum concentration of Etoposide can be increased when it is combined with Clomifene. Clomipramine The metabolism of Clomipramine can be decreased when combined with Etoposide. Clonazepam The metabolism of Clonazepam can be increased when combined with Etoposide. Clonidine The metabolism of Etoposide can be decreased when combined with Clonidine. Clopidogrel The metabolism of Etoposide can be decreased when combined with Clopidogrel. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Etoposide. Clozapine The risk or severity of neutropenia can be increased when Etoposide is combined with Clozapine. Cobicistat The metabolism of Etoposide can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Etoposide can be decreased when combined with Cobimetinib. Cocaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Cocaine. Colchicine The metabolism of Colchicine can be decreased when combined with Etoposide. Conivaptan The metabolism of Etoposide can be decreased when combined with Conivaptan. You Might Also Read Glucarpidase - Uses, Dosage, Side Effects, Interaction Copanlisib The metabolism of Copanlisib can be decreased when combined with Etoposide. Corticotropin The metabolism of Etoposide can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Etoposide can be increased when combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Etoposide. Crizotinib The metabolism of Etoposide can be decreased when combined with Crizotinib. Curcumin The metabolism of Etoposide can be decreased when combined with Curcumin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Etoposide. Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Etoposide. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Etoposide. Cyclophosphamide The metabolism of Etoposide can be increased when combined with Cyclophosphamide. Cyclosporine The serum concentration of Etoposide can be increased when it is combined with Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Etoposide. Cyproterone acetate The metabolism of Etoposide can be increased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Etoposide is combined with Cytarabine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Etoposide. Dabigatran etexilate The serum concentration of Etoposide can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Etoposide can be decreased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Etoposide is combined with Dacarbazine. Daclatasvir The serum concentration of Etoposide can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Etoposide can be increased when it is combined with Dacomitinib. Dactinomycin The risk or severity of adverse effects can be increased when Etoposide is combined with Dactinomycin. Dalfopristin The metabolism of Etoposide can be decreased when combined with Dalfopristin. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Etoposide. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Etoposide. Danazol The metabolism of Etoposide can be decreased when combined with Danazol. Dapagliflozin The metabolism of Etoposide can be decreased when combined with Dapagliflozin. Dapsone The metabolism of Etoposide can be decreased when combined with Dapsone. Daptomycin The serum concentration of Etoposide can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etoposide. Darolutamide The serum concentration of Etoposide can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Etoposide can be increased when it is combined with Darunavir. Dasabuvir The metabolism of Etoposide can be decreased when combined with Dasabuvir. Dasatinib The metabolism of Etoposide can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Etoposide can be decreased when combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Etoposide is combined with Decitabine. Deferasirox The serum concentration of Etoposide can be increased when it is combined with Deferasirox. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Etoposide. Deflazacort The metabolism of Etoposide can be increased when combined with Deflazacort. Delavirdine The metabolism of Etoposide can be decreased when combined with Delavirdine. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Etoposide. Desipramine The metabolism of Etoposide can be decreased when combined with Desipramine. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Etoposide. Deslanoside Deslanoside may decrease the cardiotoxic activities of Etoposide. Desogestrel The metabolism of Etoposide can be increased when combined with Desogestrel. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Etoposide. Desvenlafaxine The metabolism of Etoposide can be decreased when combined with Desvenlafaxine. Deucravacitinib The risk or severity of adverse effects can be increased when Etoposide is combined with Deucravacitinib. Deutetrabenazine The metabolism of Etoposide can be decreased when combined with Deutetrabenazine. Dexamethasone The metabolism of Etoposide can be increased when combined with Dexamethasone. Dexamethasone acetate The serum concentration of Etoposide can be decreased when it is combined with Dexamethasone acetate. Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Etoposide. Dexmedetomidine The metabolism of Etoposide can be decreased when combined with Dexmedetomidine. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Etoposide. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Etoposide. Dextromethorphan The metabolism of Etoposide can be decreased when combined with Dextromethorphan. Dextropropoxyphene The metabolism of Etoposide can be decreased when combined with Dextropropoxyphene. Diacerein The metabolism of Etoposide can be decreased when combined with Diacerein. Diazepam The metabolism of Etoposide can be decreased when combined with Diazepam. Diclofenac The metabolism of Etoposide can be decreased when combined with Diclofenac. Dicloxacillin The metabolism of Etoposide can be increased when combined with Dicloxacillin. Dicoumarol The therapeutic efficacy of Dicoumarol can be increased when used in combination with Etoposide. Diethylstilbestrol The metabolism of Etoposide can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Etoposide can be increased when combined with Difluocortolone. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Etoposide. Digoxin The serum concentration of Etoposide can be increased when it is combined with Digoxin. Dihydralazine The metabolism of Etoposide can be decreased when combined with Dihydralazine. Dihydroergocornine The metabolism of Etoposide can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Etoposide can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Etoposide can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Etoposide can be decreased when combined with Diltiazem. Dimethyl fumarate The risk or severity of adverse effects can be increased when Etoposide is combined with Dimethyl fumarate. Dimethyl sulfoxide The metabolism of Etoposide can be decreased when combined with Dimethyl sulfoxide. Dinutuximab The risk or severity of adverse effects can be increased when Etoposide is combined with Dinutuximab. Diosmin The serum concentration of Etoposide can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Etoposide. Diroximel fumarate The risk or severity of adverse effects can be increased when Etoposide is combined with Diroximel fumarate. Disopyramide The metabolism of Etoposide can be decreased when combined with Disopyramide. Disulfiram The metabolism of Etoposide can be decreased when combined with Disulfiram. Docetaxel The metabolism of Etoposide can be decreased when combined with Docetaxel. Dolutegravir The serum concentration of Etoposide can be increased when it is combined with Dolutegravir. Domperidone The metabolism of Etoposide can be decreased when combined with Domperidone. Doravirine The metabolism of Etoposide can be decreased when combined with Doravirine. Dosulepin The metabolism of Etoposide can be decreased when combined with Dosulepin. Doxazosin The metabolism of Etoposide can be decreased when combined with Doxazosin. Doxepin The metabolism of Doxepin can be decreased when combined with Etoposide. Doxorubicin The metabolism of Etoposide can be decreased when combined with Doxorubicin. Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Etoposide. Dronedarone The serum concentration of Etoposide can be increased when it is combined with Dronedarone. Drospirenone The metabolism of Etoposide can be decreased when combined with Drospirenone. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Etoposide. Dutasteride The metabolism of Etoposide can be decreased when combined with Dutasteride. Duvelisib The metabolism of Etoposide can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Dyclonine. Ebastine The metabolism of Etoposide can be decreased when combined with Ebastine. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Etoposide. Echinacea The metabolism of Etoposide can be increased when combined with Echinacea. Eculizumab The risk or severity of adverse effects can be increased when Etoposide is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Etoposide. Edoxaban The serum concentration of Etoposide can be increased when it is combined with Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Etoposide. Efavirenz The metabolism of Etoposide can be decreased when combined with Efavirenz. Elagolix The serum concentration of Etoposide can be increased when it is combined with Elagolix. Elbasvir The metabolism of Etoposide can be decreased when combined with Elbasvir. Elexacaftor The metabolism of Etoposide can be decreased when combined with Elexacaftor. Eliglustat The metabolism of Eliglustat can be decreased when combined with Etoposide. Eltrombopag The metabolism of Etoposide can be decreased when combined with Eltrombopag. Elvitegravir The metabolism of Etoposide can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Etoposide can be increased when combined with Emapalumab. Enasidenib The serum concentration of Etoposide can be increased when it is combined with Enasidenib. Enfortumab vedotin The serum concentration of Etoposide can be increased when it is combined with Enfortumab vedotin. Enoxacin The metabolism of Etoposide can be decreased when combined with Enoxacin. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Etoposide. Entecavir The metabolism of Etoposide can be decreased when combined with Entecavir. Entrectinib The serum concentration of Etoposide can be increased when it is combined with Entrectinib. Enzalutamide The serum concentration of Etoposide can be decreased when it is combined with Enzalutamide. Epinephrine The metabolism of Etoposide can be decreased when combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Etoposide. Eplerenone The metabolism of Etoposide can be decreased when combined with Eplerenone. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Etoposide. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Etoposide. Erdafitinib The serum concentration of Etoposide can be increased when it is combined with Erdafitinib. Ergotamine The metabolism of Etoposide can be decreased when combined with Ergotamine. Eribulin The risk or severity of adverse effects can be increased when Etoposide is combined with Eribulin. Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Etoposide. Ertugliflozin The metabolism of Etoposide can be decreased when combined with Ertugliflozin. Erythromycin The serum concentration of Etoposide can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Etoposide. Esketamine The metabolism of Etoposide can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Etoposide can be increased when combined with Eslicarbazepine. Eslicarbazepine The metabolism of Etoposide can be increased when combined with Eslicarbazepine acetate. Estetrol The metabolism of Etoposide can be decreased when combined with Estetrol. Estradiol The metabolism of Etoposide can be decreased when combined with Estradiol. Estradiol acetate The metabolism of Etoposide can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Etoposide can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Etoposide can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Etoposide can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Etoposide can be increased when combined with Estradiol valerate. Estramustine The risk or severity of adverse effects can be increased when Etoposide is combined with Estramustine. Estrone sulfate The metabolism of Etoposide can be decreased when combined with Estrone sulfate. Eszopiclone The serum concentration of Eszopiclone can be decreased when it is combined with Etoposide. Etanercept The metabolism of Etoposide can be increased when combined with Etanercept. Ethambutol The metabolism of Etoposide can be decreased when combined with Ethambutol. Ethanol The metabolism of Etoposide can be increased when combined with Ethanol. Ethinylestradiol The metabolism of Etoposide can be decreased when combined with Ethinylestradiol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Etidocaine. Etoricoxib The metabolism of Etoposide can be decreased when combined with Etoricoxib. Etravirine The metabolism of Etoposide can be increased when combined with Etravirine. Everolimus The serum concentration of Etoposide can be increased when it is combined with Everolimus. Famotidine The metabolism of Etoposide can be decreased when combined with Famotidine. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Etoposide. Favipiravir The serum concentration of Etoposide can be increased when it is combined with Favipiravir. Febuxostat The excretion of Etoposide can be decreased when combined with Febuxostat. Fedratinib The serum concentration of Etoposide can be increased when it is combined with Fedratinib. Felbamate The metabolism of Etoposide can be increased when combined with Felbamate. Felodipine The metabolism of Etoposide can be decreased when combined with Felodipine. Fenfluramine The metabolism of Etoposide can be decreased when combined with Fenfluramine. Fenofibrate The metabolism of Etoposide can be decreased when combined with Fenofibrate. Fentanyl The metabolism of Fentanyl can be decreased when combined with Etoposide. Fexinidazole The metabolism of Etoposide can be decreased when combined with Fexinidazole. Fexofenadine The serum concentration of Etoposide can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Etoposide can be increased when it is combined with Filgotinib. Finasteride The metabolism of Etoposide can be decreased when combined with Finasteride. Finerenone The serum concentration of Finerenone can be increased when it is combined with Etoposide. Fingolimod Etoposide may increase the immunosuppressive activities of Fingolimod. Flecainide The metabolism of Flecainide can be decreased when combined with Etoposide. Flibanserin The serum concentration of Etoposide can be increased when it is combined with Flibanserin. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Etoposide. Flucloxacillin The metabolism of Etoposide can be increased when combined with Flucloxacillin. Fluconazole The serum concentration of Etoposide can be increased when it is combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Etoposide is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Etoposide is combined with Fludarabine. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Etoposide. Fluindione The therapeutic efficacy of Fluindione can be increased when used in combination with Etoposide. Flunarizine The metabolism of Flunarizine can be decreased when combined with Etoposide. Flunisolide The metabolism of Etoposide can be increased when combined with Flunisolide. Flunitrazepam The metabolism of Etoposide can be decreased when combined with Flunitrazepam. Fluocinolone acetonide The metabolism of Etoposide can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Etoposide can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Etoposide can be increased when combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Etoposide. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Etoposide. Fluoxetine The metabolism of Etoposide can be decreased when combined with Fluoxetine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Etoposide. Fluprednisolone The risk or severity of adverse effects can be increased when Etoposide is combined with Fluprednisolone. Flurbiprofen The metabolism of Etoposide can be decreased when combined with Flurbiprofen. Flutamide The metabolism of Etoposide can be decreased when combined with Flutamide. Fluticasone The metabolism of Etoposide can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Etoposide can be increased when combined with Fluticasone furoate. Fluticasone propionate The metabolism of Etoposide can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Etoposide can be decreased when combined with Fluvastatin. Fluvoxamine The metabolism of Etoposide can be decreased when combined with Fluvoxamine. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Etoposide. Formestane The metabolism of Etoposide can be increased when combined with Formestane. Fosamprenavir The metabolism of Etoposide can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Etoposide can be increased when combined with Fosaprepitant. Fosnetupitant The metabolism of Etoposide can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Etoposide can be increased when combined with Fosphenytoin Fostamatinib The metabolism of Etoposide can be decreased when combined with Fostamatinib. Fostemsavir Fostemsavir may decrease the excretion rate of Etoposide which could result in a higher serum level. Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Etoposide. Fusidic acid The metabolism of Etoposide can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Etoposide can be increased when it is combined with Futibatinib. Gallium nitrate The risk or severity of adverse effects can be increased when Etoposide is combined with Gallium nitrate. Gatifloxacin The metabolism of Etoposide can be decreased when combined with Gatifloxacin. Gefitinib The metabolism of Etoposide can be decreased when combined with Gefitinib. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Etoposide. Gemfibrozil The metabolism of Etoposide can be decreased when combined with Gemfibrozil. Gemifloxacin The metabolism of Etoposide can be decreased when combined with Gemifloxacin. Gemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etoposide. Gilteritinib The metabolism of Etoposide can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Etoposide can be decreased when combined with Ginkgo biloba. Givosiran The serum concentration of Etoposide can be increased when it is combined with Givosiran. Glasdegib The serum concentration of Etoposide can be increased when it is combined with Glasdegib. Glatiramer The risk or severity of adverse effects can be increased when Etoposide is combined with Glatiramer. Glecaprevir The serum concentration of Etoposide can be increased when it is combined with Glecaprevir. Glyburide The metabolism of Etoposide can be decreased when combined with Glyburide. Glycerol The metabolism of Etoposide can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Etoposide can be increased when combined with Golimumab. Grazoprevir Grazoprevir may decrease the excretion rate of Etoposide which could result in a higher serum level. Grepafloxacin The metabolism of Etoposide can be decreased when combined with Grepafloxacin. Griseofulvin The metabolism of Etoposide can be increased when combined with Griseofulvin. Guanabenz The metabolism of Etoposide can be decreased when combined with Guanabenz. Guselkumab The risk or severity of adverse effects can be increased when Etoposide is combined with Guselkumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Etoposide. Halofantrine The metabolism of Etoposide can be decreased when combined with Halofantrine. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Etoposide. Heparin The risk or severity of bleeding can be increased when Heparin is combined with Etoposide. Hepatitis A Vaccine The therapeutic efficacy of the Hepatitis A Vaccine can be decreased when used in combination with Etoposide. Hepatitis B Vaccine The therapeutic efficacy of the Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Etoposide. Human adenovirus The risk or severity of infection can be increased when the Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Etoposide. Hydralazine The metabolism of Etoposide can be decreased when combined with Hydralazine. Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Etoposide. Hydrocortamate The metabolism of Etoposide can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Etoposide can be increased when combined with Hydrocortisone. Hydrocortisone acetate The metabolism of Etoposide can be increased when combined with Hydrocortisone acetate. Hydrocortisone butyrate The metabolism of Etoposide can be increased when combined with Hydrocortisone butyrate. Hydrocortisone The metabolism of Etoposide can be decreased when combined with Hydrocortisone cypionate. Hydrocortisone phosphate The metabolism of Etoposide can be decreased when combined with Hydrocortisone phosphate. Hydrocortisone succinate The metabolism of Etoposide can be increased when combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Etoposide. Hydroxychloroquine The risk or severity of adverse effects can be increased when Etoposide is combined with Hydroxychloroquine. Hydroxyprogesterone The metabolism of Etoposide can be decreased when combined with Hydroxyprogesterone caproate. Hydroxyurea The risk or severity of adverse effects can be increased when Etoposide is combined with Hydroxyurea. Hydroxyzine The metabolism of Etoposide can be decreased when combined with Hydroxyzine. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etoposide. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Etoposide. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Etoposide. Idarubicin The risk or severity of adverse effects can be increased when Etoposide is combined with Idarubicin. Idelalisib The risk or severity of adverse effects can be increased when Etoposide is combined with Idelalisib. Ifosfamide The metabolism of Ifosfamide can be increased when combined with Etoposide. Iloperidone The metabolism of Iloperidone can be decreased when combined with Etoposide. Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Etoposide. Imatinib The serum concentration of Etoposide can be increased when it is combined with Imatinib. Imipramine The metabolism of Etoposide can be decreased when combined with Imipramine. Indacaterol The serum concentration of Etoposide can be increased when it is combined with Indacaterol. Indinavir The metabolism of Etoposide can be decreased when combined with Indinavir. Indomethacin The metabolism of Etoposide can be decreased when combined with Indomethacin. Inebilizumab The risk or severity of infection can be increased when Etoposide is combined with Inebilizumab. Infigratinib The metabolism of Etoposide can be decreased when combined with Infigratinib. Infliximab The metabolism of Etoposide can be increased when combined with Infliximab. You Might Also Read Sucralfate; Uses, Dosage, Side Effects, Drug Interactions Ketoconazole The metabolism of Etoposide can be decreased when combined with Ketoconazole. Lacosamide The metabolism of Etoposide can be decreased when combined with Lacosamide. Lamotrigine The metabolism of Etoposide can be increased when combined with Lamotrigine. Lanreotide The metabolism of Etoposide can be decreased when combined with Lanreotide. Lansoprazole Lansoprazole may decrease the excretion rate of Etoposide which could result in a higher serum level. Lapatinib The serum concentration of Etoposide can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Etoposide can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Etoposide can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Etoposide can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Etoposide can be increased when it is combined with Lefamulin. Leflunomide The risk or severity of adverse effects can be increased when Etoposide is combined with Leflunomide. Lemborexant The serum concentration of Lemborexant can be decreased when it is combined with Etoposide. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Etoposide. Lenvatinib The serum concentration of Etoposide can be increased when it is combined with Lenvatinib. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Etoposide. Lercanidipine The metabolism of Etoposide can be decreased when combined with Lercanidipine. Lesinurad The metabolism of Etoposide can be increased when combined with Lesinurad. Letermovir The metabolism of Etoposide can be decreased when combined with Letermovir. Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Etoposide. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Levobupivacaine. Levoketoconazole The metabolism of Etoposide can be decreased when combined with Levoketoconazole. Levomilnacipran The metabolism of Levomilnacipran can be increased when combined with Etoposide. Levonorgestrel The metabolism of Etoposide can be decreased when combined with Levonorgestrel. Levothyroxine The serum concentration of Etoposide can be decreased when it is combined with Levothyroxine. Lidocaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Lidocaine. Linagliptin The serum concentration of Etoposide can be increased when it is combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Etoposide. Lipegfilgrastim Etoposide may increase the myelosuppressive activities of Lipegfilgrastim. Lofexidine The metabolism of Lofexidine can be decreased when combined with Etoposide. Lomefloxacin The metabolism of Lomefloxacin can be decreased when combined with Etoposide. Lomitapide The serum concentration of Etoposide can be increased when it is combined with Lomitapide. Lomustine The risk or severity of adverse effects can be increased when Etoposide is combined with Lomustine. Lonafarnib The metabolism of Etoposide can be decreased when combined with Lonafarnib. Lonapegsoma The metabolism of Etoposide can be increased when combined with Lonapegsomatropin. Loncastuximab The serum concentration of Etoposide can be increased when it is combined with Loncastuximab tesirine. Loperamide The serum concentration of Etoposide can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Etoposide can be increased when it is combined with Lopinavir. Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Etoposide. Lorlatinib The serum concentration of Etoposide can be decreased when it is combined with Lorlatinib. Losartan The metabolism of Etoposide can be decreased when combined with Losartan. Lovastatin The metabolism of Lovastatin can be decreased when combined with Etoposide. Loxapine The serum concentration of Etoposide can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Etoposide can be decreased when it is combined with Lumacaftor. Lumateperone The serum concentration of Lumateperone can be decreased when it is combined with Etoposide. Lusutrombopag The serum concentration of Etoposide can be increased when it is combined with Lusutrombopag. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Etoposide. Manidipine The metabolism of Etoposide can be decreased when combined with Manidipine. Mannitol The serum concentration of Etoposide can be increased when it is combined with Mannitol. Maprotiline The metabolism of Maprotiline can be decreased when combined with Etoposide. Maribavir The serum concentration of Etoposide can be increased when it is combined with Maribavir. Mavacamten The serum concentration of Etoposide can be decreased when it is combined with Mavacamten. Measles virus vaccine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Etoposide. Mechlorethamine The risk or severity of adverse effects can be increased when Etoposide is combined with Mechlorethamine. Medroxyprogesterone The metabolism of Etoposide can be increased when combined with Medroxyprogesterone acetate. Mefenamic acid The metabolism of Mefenamic acid can be decreased when combined with Etoposide. Mefloquine The serum concentration of Etoposide can be increased when it is combined with Mefloquine. Melatonin The metabolism of Melatonin can be decreased when combined with Etoposide. Meloxicam The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Etoposide is combined with Melphalan. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Etoposide. Meperidine The metabolism of Etoposide can be decreased when combined with Meperidine. Mephenytoin The metabolism of Etoposide can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Etoposide is combined with Mepolizumab. Meprednisone The metabolism of Etoposide can be increased when combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Etoposide is combined with Mercaptopurine. Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Etoposide. Methadone The metabolism of Etoposide can be decreased when combined with Methadone. Methimazole The metabolism of Etoposide can be decreased when combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Etoposide. Methoxsalen The metabolism of Etoposide can be decreased when combined with Methoxsalen. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Etoposide. Methylene blue The serum concentration of Etoposide can be increased when it is combined with Methylene blue. Methylergometrine The metabolism of Etoposide can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Etoposide can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Etoposide can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Etoposide can be decreased when combined with Methylprednisone. Methysergide The metabolism of Etoposide can be decreased when combined with Methysergide. Metoclopramide The metabolism of Metoclopramide can be decreased when combined with Etoposide. Metreleptin The metabolism of Etoposide can be increased when combined with Metreleptin. Metronidazole The metabolism of Etoposide can be decreased when combined with Metronidazole. Metyrapone The metabolism of Etoposide can be increased when combined with Metyrapone. Mexiletine The metabolism of Etoposide can be decreased when combined with Mexiletine. Mianserin The metabolism of Mianserin can be decreased when combined with Etoposide. Miconazole The metabolism of Etoposide can be decreased when combined with Miconazole. Midazolam The serum concentration of Midazolam can be increased when it is combined with Etoposide. Midostaurin The metabolism of Etoposide can be decreased when combined with Midostaurin. Mifepristone The serum concentration of Etoposide can be decreased when it is combined with Mifepristone. Milnacipran The metabolism of Milnacipran can be increased when combined with Etoposide. Miocamycin The metabolism of Etoposide can be decreased when combined with Miocamycin. Mirabegron The serum concentration of Etoposide can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Etoposide can be decreased when combined with Mirtazapine. Mirvetuximab Soravtansine The metabolism of Etoposide can be decreased when combined with Mirvetuximab Soravtansine. Mitapivat The metabolism of Etoposide can be increased when combined with Mitapivat. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Etoposide. Mitotane The metabolism of Etoposide can be increased when combined with Mitotane. Mitoxantrone The risk or severity of adverse effects can be increased when Etoposide is combined with Mitoxantrone. Mobocertinib The serum concentration of Etoposide can be decreased when it is combined with Mobocertinib. Modafinil The metabolism of Etoposide can be increased when combined with Modafinil. Moderna COVID The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Etoposide. Modified vaccinia The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Etoposide. Mometasone furoate The metabolism of Etoposide can be increased when combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Etoposide is combined with Monomethyl fumarate. Morphine The serum concentration of Etoposide can be increased when it is combined with Morphine. Mosunetuzumab The metabolism of Etoposide can be decreased when combined with Mosunetuzumab. Moxifloxacin The metabolism of Etoposide can be decreased when combined with Moxifloxacin. Mumps virus The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Etoposide. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Etoposide. Mycophenolate mofetil The metabolism of Etoposide can be decreased when combined with Mycophenolate mofetil. Mycophenolic acid The risk or severity of adverse effects can be increased when Etoposide is combined with Mycophenolic acid. Nabumetone The metabolism of Etoposide can be decreased when combined with Nabumetone. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Etoposide. Nafcillin The metabolism of Etoposide can be increased when combined with Nafcillin. Nalidixic acid The metabolism of Etoposide can be decreased when combined with Nalidixic acid. Naloxone The metabolism of Etoposide can be decreased when combined with Naloxone. Naproxen The metabolism of Naproxen can be decreased when combined with Etoposide. Natalizumab The risk or severity of adverse effects can be increased when Etoposide is combined with Natalizumab. Nateglinide The metabolism of Etoposide can be decreased when combined with Nateglinide. Nefazodone The metabolism of Etoposide can be decreased when combined with Nefazodone. Nelarabine The risk or severity of adverse effects can be increased when Etoposide is combined with Nelarabine. Nelfinavir The metabolism of Etoposide can be decreased when combined with Nelfinavir. Neratinib The serum concentration of Etoposide can be increased when it is combined with Neratinib. Netupitant The serum concentration of Etoposide can be increased when it is combined with Netupitant. Nevirapine The metabolism of Etoposide can be decreased when combined with Nevirapine. Niacin The metabolism of Etoposide can be decreased when combined with Niacin. Nicardipine The metabolism of Etoposide can be decreased when combined with Nicardipine. Niclosamide The metabolism of Etoposide can be decreased when combined with Niclosamide. Nifedipine The metabolism of Etoposide can be decreased when combined with Nifedipine. Nilotinib The metabolism of Etoposide can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Etoposide can be decreased when combined with Nilvadipine. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Etoposide. Nintedanib The metabolism of Etoposide can be decreased when combined with Nintedanib. Nisoldipine The metabolism of Etoposide can be decreased when combined with Nisoldipine. Nitrendipine The metabolism of Etoposide can be decreased when combined with Nitrendipine. Norethisterone The metabolism of Etoposide can be decreased when combined with Norethisterone. Norfloxacin The metabolism of Etoposide can be decreased when combined with Norfloxacin. Norgestimate The serum concentration of Etoposide can be increased when it is combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Etoposide. Noscapine The metabolism of Etoposide can be decreased when combined with Noscapine. Novobiocin Novobiocin may decrease the excretion rate of Etoposide which could result in a higher serum level. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Etoposide. Obeticholic acid The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Etoposide. Obinutuzumab The risk or severity of adverse effects can be increased when Etoposide is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Etoposide. Octreotide The serum concentration of Etoposide can be increased when it is combined with Octreotide. Ofatumumab The risk or severity of adverse effects can be increased when Etoposide is combined with Ofatumumab. Olanzapine The metabolism of Etoposide can be decreased when combined with Olanzapine. Olaparib The metabolism of Etoposide can be decreased when combined with Olaparib. Oliceridine The serum concentration of Oliceridine can be decreased when it is combined with Etoposide. Omadacycline The serum concentration of Etoposide can be increased when it is combined with Omadacycline. Ombitasvir The metabolism of Etoposide can be decreased when combined with Ombitasvir. Omeprazole The metabolism of Etoposide can be increased when combined with Omeprazole. Ondansetron The metabolism of Etoposide can be decreased when combined with Ondansetron. Oritavancin The metabolism of Etoposide can be increased when combined with Oritavancin. Orphenadrine The metabolism of Etoposide can be decreased when combined with Orphenadrine. Osilodrostat The serum concentration of Etoposide can be increased when it is combined with Osilodrostat. Osimertinib The serum concentration of Etoposide can be decreased when it is combined with Osimertinib. Oteseconazole The serum concentration of Etoposide can be increased when it is combined with Oteseconazole. Ouabain Ouabain may decrease the cardiotoxic activities of Etoposide. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Etoposide. Oxcarbazepine The metabolism of Etoposide can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Oxetacaine. Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Etoposide. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Oxybuprocaine. Oxybutynin The metabolism of Etoposide can be decreased when combined with Oxybutynin. Oxycodone The metabolism of Etoposide can be decreased when combined with Oxycodone. Ozanimod The risk or severity of adverse effects can be increased when Etoposide is combined with Ozanimod. Paclitaxel The metabolism of Etoposide can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Etoposide can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Etoposide can be increased when it is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Etoposide. Paliperidone The serum concentration of Etoposide can be increased when it is combined with Paliperidone. Panobinostat The risk or severity of adverse effects can be increased when Etoposide is combined with Panobinostat. Pantoprazole Pantoprazole may decrease the excretion rate of Etoposide which could result in a higher serum level. Paritaprevir The metabolism of Etoposide can be decreased when combined with Paritaprevir. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Etoposide. Paroxetine The metabolism of Etoposide can be decreased when combined with Paroxetine. Pasireotide The metabolism of Etoposide can be decreased when combined with Pasireotide. Pazopanib The metabolism of Etoposide can be decreased when combined with Pazopanib. Pefloxacin The metabolism of Etoposide can be decreased when combined with Pefloxacin. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Etoposide. Pegcetacoplan The risk or severity of adverse effects can be increased when Etoposide is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Etoposide. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Etoposide. Peginterferon alfa-2b The serum concentration of Etoposide can be increased when it is combined with Peginterferon alfa-2b. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Etoposide is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Etoposide. Penciclovir The metabolism of Etoposide can be decreased when combined with Penciclovir. Penicillamine The risk or severity of adverse effects can be increased when Etoposide is combined with Penicillamine. Pentamidine The metabolism of Etoposide can be decreased when combined with Pentamidine. Pentobarbital The metabolism of Etoposide can be increased when combined with Pentobarbital. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Etoposide. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Etoposide. Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Etoposide. Perampanel The metabolism of Perampanel can be increased when combined with Etoposide. Perphenazine The metabolism of Perphenazine can be decreased when combined with Etoposide. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Etoposide. Pertuzumab The risk or severity of cardiotoxicity can be increased when Etoposide is combined with Pertuzumab. Phenobarbital The metabolism of Etoposide can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Phenol. Phenprocoumon The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Etoposide. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Etoposide. Phenylbutazone The metabolism of Etoposide can be increased when combined with Phenylbutazone. Phenylephrine The metabolism of Etoposide can be increased when combined with Phenylephrine. Phenytoin The metabolism of Etoposide can be increased when combined with Phenytoin. Pibrentasvir The serum concentration of Etoposide can be increased when it is combined with Pibrentasvir. Pimavanserin The metabolism of Etoposide can be decreased when combined with Pimavanserin. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoposide. Pimozide The metabolism of Pimozide can be decreased when combined with Etoposide. Piperaquine The metabolism of Etoposide can be decreased when combined with Piperaquine. Pirfenidone The risk or severity of adverse effects can be increased when Etoposide is combined with Pirfenidone. Pitolisant The serum concentration of Etoposide can be decreased when it is combined with Pitolisant. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Etoposide. Pomalidomide The risk or severity of adverse effects can be increased when Etoposide is combined with Pomalidomide. Ponatinib The serum concentration of Etoposide can be increased when it is combined with Ponatinib. Ponesimod The metabolism of Etoposide can be decreased when combined with Ponesimod. Posaconazole The metabolism of Etoposide can be decreased when combined with Posaconazole. Pralatrexate The risk or severity of adverse effects can be increased when Etoposide is combined with Pralatrexate. Pralsetinib The serum concentration of Etoposide can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Etoposide. Pravastatin Pravastatin may decrease the excretion rate of Etoposide which could result in a higher serum level. Praziquantel The metabolism of Etoposide can be decreased when combined with Praziquantel. Prednisolone The metabolism of Etoposide can be increased when combined with Prednisolone. Prednisolone acetate The metabolism of Etoposide can be increased when combined with Prednisolone acetate. Prednisolone phosphate The serum concentration of Etoposide can be decreased when it is combined with Prednisolone phosphate. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Etoposide. Prednisone acetate The metabolism of Etoposide can be increased when combined with Prednisone acetate. Pretomanid The metabolism of Etoposide can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Prilocaine. Primaquine The metabolism of Etoposide can be decreased when combined with Primaquine. Primidone The metabolism of Etoposide can be increased when combined with Primidone. Probenecid The metabolism of Etoposide can be increased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Etoposide is combined with Procarbazine. Progesterone The metabolism of Etoposide can be decreased when combined with Progesterone. Promazine The metabolism of Etoposide can be decreased when combined with Promazine. Propafenone The serum concentration of Etoposide can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Proparacaine. Propofol The metabolism of Etoposide can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Propoxycaine. Propranolol The metabolism of Etoposide can be decreased when combined with Propranolol. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Etoposide. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Etoposide. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Etoposide. Prucalopride The metabolism of Prucalopride can be decreased when combined with Etoposide. Quetiapine The metabolism of Etoposide can be decreased when combined with Quetiapine. Quinidine The serum concentration of Etoposide can be increased when it is combined with Quinidine. Quinine The serum concentration of Etoposide can be increased when it is combined with Quinine. Quinupristin The metabolism of Etoposide can be decreased when combined with Quinupristin. Rabeprazole Rabeprazole may decrease the excretion rate of Etoposide which could result in a higher serum level. Rabies immune The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Etoposide. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Etoposide. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Etoposide. Raloxifene The metabolism of Etoposide can be decreased when combined with Raloxifene. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Etoposide. Ramelteon The metabolism of Ramelteon can be decreased when combined with Etoposide. Ranitidine The metabolism of Ranitidine can be decreased when combined with Etoposide. Ranolazine The metabolism of Ranolazine can be increased when combined with Etoposide. Rasagiline The metabolism of Rasagiline can be decreased when combined with Etoposide. Ravulizumab The risk or severity of adverse effects can be increased when Etoposide is combined with Ravulizumab. Regorafenib The serum concentration of Etoposide can be increased when it is combined with Regorafenib. Relugolix The metabolism of Etoposide can be decreased when combined with Relugolix. Remdesivir The metabolism of Etoposide can be decreased when combined with Remdesivir. Reserpine The serum concentration of Etoposide can be increased when it is combined with Reserpine. Retapamulin The metabolism of Retapamulin can be decreased when combined with Etoposide. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Etoposide. Revefenacin The serum concentration of Etoposide can be increased when it is combined with Revefenacin. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Etoposide. Ribociclib The metabolism of Etoposide can be decreased when combined with Ribociclib. Rifabutin The metabolism of Etoposide can be increased when combined with Rifabutin. Rifampicin The serum concentration of Etoposide can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Etoposide can be increased when it is combined with Rifamycin. Rifapentine The metabolism of Etoposide can be increased when combined with Rifapentine. Rilonacept The metabolism of Etoposide can be increased when combined with Rilonacept. Rilpivirine The serum concentration of Rilpivirine can be decreased when it is combined with Etoposide. Riluzole The metabolism of Etoposide can be decreased when combined with Riluzole. Rimegepant The metabolism of Rimegepant can be increased when combined with Etoposide. Riociguat The serum concentration of Etoposide can be increased when it is combined with Riociguat. Ripretinib The serum concentration of Etoposide can be increased when it is combined with Ripretinib. Risankizumab The risk or severity of adverse effects can be increased when Etoposide is combined with Risankizumab. Risperidone The metabolism of Etoposide can be decreased when combined with Risperidone. Ritonavir The serum concentration of Etoposide can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Etoposide. Rivaroxaban The metabolism of Etoposide can be decreased when combined with Rivaroxaban. Rofecoxib The metabolism of Etoposide can be increased when combined with Rofecoxib. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Etoposide. Rolapitant The serum concentration of Etoposide can be increased when it is combined with Rolapitant. Romidepsin The metabolism of Etoposide can be decreased when combined with Romidepsin. Ropeginterferon The risk or severity of adverse effects can be increased when Etoposide is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Ropivacaine. Rosoxacin The metabolism of Etoposide can be decreased when combined with Rosoxacin. Rosuvastatin The metabolism of Etoposide can be decreased when combined with Rosuvastatin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Etoposide. Roxadustat The serum concentration of Etoposide can be increased when it is combined with Roxadustat. Roxithromycin The metabolism of Etoposide can be decreased when combined with Roxithromycin. You Might Also Read Peroxetine; Uses, Dosage, Side Effects, Interactions Rufinamide The metabolism of Etoposide can be increased when combined with Rufinamide. Ruxolitinib The risk or severity of adverse effects can be increased when Etoposide is combined with Ruxolitinib. Safinamide Safinamide may decrease the excretion rate of Etoposide which could result in a higher serum level. Salmeterol The metabolism of Etoposide can be decreased when combined with Salmeterol. Sapropterin The serum concentration of Etoposide can be increased when it is combined with Sapropterin. Saquinavir The metabolism of Etoposide can be decreased when combined with Saquinavir. Recycling The serum concentration of Etoposide can be increased when it is combined with Sarecycline. Sarilumab The metabolism of Etoposide can be increased when combined with Sarilumab. Natalizumab The serum concentration of Etoposide can be decreased when it is combined with Satralizumab. Saxagliptin The metabolism of Etoposide can be decreased when combined with Saxagliptin. Secobarbital The metabolism of Etoposide can be increased when combined with Secobarbital. Secukinumab The metabolism of Etoposide can be increased when combined with Secukinumab. Progesterone acetate The metabolism of Segesterone acetate can be increased when combined with Etoposide. Selegiline The metabolism of Selegiline can be decreased when combined with Etoposide. Selexipag The serum concentration of Etoposide can be increased when it is combined with Selexipag. Selpercatinib The serum concentration of Selpercatinib can be decreased when it is combined with Etoposide. Selumetinib The metabolism of Etoposide can be decreased when combined with Selumetinib. Sildenafil The serum concentration of Etoposide can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Etoposide can be increased when it is combined with Silodosin. Siltuximab The metabolism of Etoposide can be increased when combined with Siltuximab. Simeprevir The serum concentration of Etoposide can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Etoposide can be increased when it is combined with Simvastatin. Siponimod The risk or severity of adverse effects can be increased when Etoposide is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etoposide. Sirolimus The metabolism of Sirolimus can be decreased when combined with Etoposide. Sitagliptin The serum concentration of Etoposide can be increased when it is combined with Sitagliptin. Sitaxentan The metabolism of Etoposide can be decreased when combined with Sitaxentan. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Etoposide. Sodium The metabolism of Etoposide can be decreased when combined with Sodium aurothiomalate. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Etoposide. Sofosbuvir The serum concentration of Etoposide can be increased when it is combined with Sofosbuvir. Somapacitan The metabolism of Etoposide can be increased when combined with Somapacitan. Somatostatin The metabolism of Etoposide can be decreased when combined with Somatostatin. Somatotropin The metabolism of Etoposide can be increased when combined with Somatotropin. Somatrem The metabolism of Etoposide can be increased when combined with Somatrem. Somatrogon The metabolism of Etoposide can be increased when combined with Somatrogon. Sorafenib The serum concentration of Etoposide can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Etoposide can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Etoposide can be decreased when it is combined with Sotorasib. Spesolimab The risk or severity of adverse effects can be increased when Etoposide is combined with Spesolimab. St. John’s Wort The serum concentration of Etoposide can be decreased when it is combined with St. John’s Wort. Stiripentol The metabolism of Etoposide can be decreased when combined with Stiripentol. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Etoposide. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Etoposide. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Etoposide. Sulfasalazine The risk or severity of adverse effects can be increased when Etoposide is combined with Sulfasalazine. Sulfinpyrazone The metabolism of Etoposide can be increased when combined with Sulfinpyrazone. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Etoposide. Sunitinib The metabolism of Sunitinib can be decreased when combined with Etoposide. Suvorexant The serum concentration of Etoposide can be increased when it is combined with Suvorexant. Tacrine The metabolism of Etoposide can be decreased when combined with Tacrine. Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Etoposide. Tadalafil The metabolism of Etoposide can be decreased when combined with Tadalafil. Tafamidis The serum concentration of Etoposide can be increased when it is combined with Tafamidis. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Etoposide. Tamoxifen The serum concentration of Etoposide can be increased when it is combined with Tamoxifen. Tasimelteon The metabolism of Etoposide can be decreased when combined with Tasimelteon. Taurocholic acid Taurocholic acid may decrease the excretion rate of Etoposide which could result in a higher serum level. Tazemetostat The metabolism of Etoposide can be decreased when combined with Tazemetostat. Technetium The serum concentration of Etoposide can be increased when it is combined with Technetium Tc-99m sestamibi. Tecovirimat The metabolism of Etoposide can be increased when combined with Tecovirimat. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Etoposide is combined with Tedizolid phosphate. Tegafur The metabolism of Tegafur can be decreased when combined with Etoposide. Tegaserod The metabolism of Etoposide can be decreased when combined with Tegaserod. Telaprevir The metabolism of Etoposide can be decreased when combined with Telaprevir. Telithromycin The metabolism of Etoposide can be decreased when combined with Telithromycin. Telmisartan Telmisartan may decrease the excretion rate of Etoposide which could result in a higher serum level. Telotristat ethyl The serum concentration of Etoposide can be decreased when it is combined with Telotristat ethyl. Temozolomide The risk or severity of adverse effects can be increased when Etoposide is combined with Temozolomide. Temsirolimus The serum concentration of Etoposide can be increased when it is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Etoposide. Teniposide The metabolism of Etoposide can be decreased when combined with Teniposide. Tenofovir alafenamide The metabolism of Etoposide can be decreased when combined with Tenofovir alafenamide. Tenofovir disoproxil The serum concentration of Etoposide can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Etoposide can be increased when it is combined with Tepotinib. Teprotumumab The risk or severity of adverse effects can be increased when Etoposide is combined with Teprotumumab. Terbinafine The metabolism of Etoposide can be increased when combined with Terbinafine. Terfenadine The metabolism of Etoposide can be decreased when combined with Terfenadine. Teriflunomide The serum concentration of Etoposide can be decreased when it is combined with Teriflunomide. Testosterone The metabolism of Etoposide can be increased when combined with Testosterone. Testosterone The metabolism of Etoposide can be decreased when combined with Testosterone cypionate. Testosterone The metabolism of Etoposide can be decreased when combined with Testosterone enanthate. Testosterone propionate The metabolism of Etoposide can be increased when combined with Testosterone propionate. Tetracaine The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Tetracaine. Tetracycline The metabolism of Etoposide can be decreased when combined with Tetracycline. Tezacaftor The metabolism of Etoposide can be decreased when combined with Tezacaftor. Thalidomide The risk or severity of adverse effects can be increased when Etoposide is combined with Thalidomide. Theophylline The metabolism of Etoposide can be decreased when combined with Theophylline. Thiabendazole The metabolism of Etoposide can be decreased when combined with Thiabendazole. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Etoposide. Tivozanib The metabolism of Tivozanib can be increased when combined with Etoposide. Tixocortol The risk or severity of adverse effects can be increased when Etoposide is combined with Tixocortol. Tizanidine The metabolism of Etoposide can be decreased when combined with Tizanidine. Tocainide The metabolism of Etoposide can be decreased when combined with Tocainide. Tocilizumab The metabolism of Etoposide can be increased when combined with Tocilizumab. Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Etoposide. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Etoposide. Topiramate The metabolism of Etoposide can be increased when combined with Topiramate. Topotecan The risk or severity of adverse effects can be increased when Etoposide is combined with Topotecan. Toremifene The serum concentration of Etoposide can be increased when it is combined with Toremifene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Etoposide. Trabectedin The risk or severity of adverse effects can be increased when Etoposide is combined with Trabectedin. Tramadol The metabolism of Tramadol can be decreased when combined with Etoposide. Trastuzumab Trastuzumab may increase the neutropenic activities of Etoposide. Trastuzumab The metabolism of Trastuzumab emtansine can be decreased when combined with Etoposide. Trazodone The serum concentration of Etoposide can be decreased when it is combined with Trazodone. Tretinoin The metabolism of Etoposide can be decreased when combined with Tretinoin. Triamcinolone The metabolism of Etoposide can be increased when combined with Triamcinolone. Triamterene The metabolism of Etoposide can be decreased when combined with Triamterene. Triazolam The metabolism of Etoposide can be decreased when combined with Triazolam. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Etoposide. Triclabendazole The metabolism of Etoposide can be decreased when combined with Triclabendazole. Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Etoposide. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Etoposide. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Etoposide. Trilaciclib The metabolism of Etoposide can be increased when combined with Trilaciclib. Trilostane The risk or severity of adverse effects can be increased when Etoposide is combined with Trilostane. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Etoposide. Troglitazone The metabolism of Etoposide can be increased when combined with Troglitazone. Troleandomycin The metabolism of Etoposide can be decreased when combined with Troleandomycin. Trovafloxacin The metabolism of Etoposide can be decreased when combined with Trovafloxacin. Tucatinib Tucatinib may decrease the excretion rate of Etoposide which could result in a higher serum level. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Etoposide. Typhoid Vaccine The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Etoposide. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Etoposide. Ubrogepant The serum concentration of Etoposide can be increased when it is combined with Ubrogepant. Udenafil The metabolism of Etoposide can be decreased when combined with Udenafil. Umbralisib The serum concentration of Etoposide can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Etoposide can be increased when it is combined with Umeclidinium. Upadacitinib The risk or severity of adverse effects can be increased when Etoposide is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Etoposide. Valbenazine The metabolism of Etoposide can be decreased when combined with Valbenazine. Valproic acid The metabolism of Etoposide can be decreased when combined with Valproic acid. Vandetanib The serum concentration of Etoposide can be increased when it is combined with Vandetanib. Vardenafil The metabolism of Vardenafil can be decreased when combined with Etoposide. Varicella zoster The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Etoposide. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Etoposide. Vedolizumab The risk or severity of adverse effects can be increased when Etoposide is combined with Vedolizumab. Velpatasvir The serum concentration of Etoposide can be increased when it is combined with Velpatasvir. Vemurafenib The serum concentration of Etoposide can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Etoposide can be increased when it is combined with Venetoclax. Venlafaxine Venlafaxine may increase the excretion rate of Etoposide which could result in a lower serum level and potentially a reduction in efficacy. Verapamil The serum concentration of Etoposide can be increased when it is combined with Verapamil. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Etoposide. Vilanterol The risk or severity of adverse effects can be increased when Etoposide is combined with Vilanterol. Viloxazine The metabolism of Etoposide can be decreased when combined with Viloxazine. Vinblastine The metabolism of Etoposide can be increased when combined with Vinblastine. Vincristine The metabolism of Etoposide can be decreased when combined with Vincristine. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Etoposide. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Etoposide. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Etoposide. Vismodegib Vismodegib may decrease the excretion rate of Etoposide which could result in a higher serum level. Vitamin E The metabolism of Etoposide can be increased when combined with Vitamin E. Voclosporin The serum concentration of Etoposide can be increased when it is combined with Voclosporin. Vonoprazan The metabolism of Etoposide can be decreased when combined with Vonoprazan. Vorapaxar The serum concentration of Etoposide can be increased when it is combined with Vorapaxar. Voriconazole The metabolism of Etoposide can be decreased when combined with Voriconazole. Vorinostat The risk or severity of adverse effects can be increased when Etoposide is combined with Vorinostat. Vortioxetine The metabolism of Etoposide can be decreased when combined with Vortioxetine. Voxelotor The serum concentration of Etoposide can be increased when it is combined with Voxelotor. Voxilaprevir The serum concentration of Etoposide can be increased when it is combined with Voxilaprevir. Warfarin The therapeutic efficacy of Warfarin can be increased when used in combination with Etoposide. Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Etoposide. Yellow fever vaccine The risk or severity of infection can be increased when Yellow fever vaccine is combined with Etoposide. Zafirlukast The metabolism of Etoposide can be decreased when combined with Zafirlukast. Zaleplon The metabolism of Etoposide can be decreased when combined with Zaleplon. Zidovudine The metabolism of Etoposide can be increased when combined with Zidovudine. Zileuton The metabolism of Etoposide can be decreased when combined with Zileuton. Zimelidine The metabolism of Etoposide can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Etoposide can be decreased when combined with Ziprasidone. Zolmitriptan The metabolism of Etoposide can be decreased when combined with Zolmitriptan. Zolpidem The metabolism of Etoposide can be decreased when combined with Zolpidem. Zonisamide The serum concentration of Etoposide can be increased when it is combined with Zonisamide. Pregnancy and Lactation AU TGA pregnancy category D US FDA pregnancy category D Pregnancy Etoposide can cause harm to the unborn baby when it is taken by pregnant women. It should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking this medication, contact your doctor immediately. Etoposide can cause changes to sperm in men, decreasing fertility. Women and men receiving etoposide should use effective contraceptive methods. Lactation Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. It might be possible to breastfeed safely during intermittent therapy with etoposide after an appropriate period of breastfeeding abstinence. A period of at least 24 hours is required after a dose of 80 mg/sq. m. or less. Others have suggested an abstinence period of 72 hours after etoposide use.[1] Chemotherapy may adversely affect the normal microbiome and chemical makeup of breast milk. Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant. How should this medicine be used? Etoposide comes as a capsule to take by mouth. It is usually taken once a day for 4 or 5 days in a row. This cycle may be repeated once every 3 to 4 weeks, depending on your response to the medication. The length of treatment depends on the types of drugs you are taking, how well your body responds to them, and the type of cancer you have. Take etoposide at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take etoposide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. What special precautions should I follow? Before taking etoposide, tell your doctor and pharmacist if you are allergic to etoposide, any other medications, or any of the ingredients in etoposide capsules. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: cisplatin (Platinol), and cyclosporine (Gengraf, Neoral, Sandimmune). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with etoposide, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor if you have or have ever had kidney disease. tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You should not become pregnant or breast-feed while you are taking etoposide. If you become pregnant while taking etoposide, call your doctor. Etoposide may harm the fetus. References https://pubchem.ncbi.nlm.nih.gov/compound/Etoposide https://pubchem.ncbi.nlm.nih.gov/compound/Etoposide-phosphate https://pubchem.ncbi.nlm.nih.gov/compound/Etoposide-toniribate https://medlineplus.gov/druginfo/meds/a684055.html https://www.drugs.com/mtm/etoposide.html https://www.ncbi.nlm.nih.gov/books/NBK557864/ https://go.drugbank.com/drugs/DB00773 https://en.wikipedia.org/wiki/Etoposide https://www.cancer.gov/about-cancer/treatment/drugs/etoposidephosphate ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL44657/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=D005047 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/ETOPOSIDE DrugBank https://www.drugbank.ca/legal/terms_of_use Etoposide https://www.drugbank.ca/drugs/DB00773 IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6815 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Etoposide http://idrblab.net/ttd/data/drug/details/D0B7EB CAS Common Chemistry LICENSE The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. https://creativecommons.org/licenses/by-nc/4.0/ Etoposide https://commonchemistry.cas.org/detail?cas_rn=33419-42-0 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Etoposide [USAN:USP:INN:BAN:JAN] https://chem.nlm.nih.gov/chemidplus/sid/0033419420 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Etoposide https://comptox.epa.gov/dashboard/DTXSID5023035 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice Etoposide https://echa.europa.eu/substance-information/-/substanceinfo/100.046.812 Etoposide https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/87596 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking ETOPOSIDE https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6PLQ3CP4P3 Hazardous Substances Data Bank (HSDB) ETOPOSIDE https://pubchem.ncbi.nlm.nih.gov/source/hsdb/6517 Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Etoposide http://www.hmdb.ca/metabolites/HMDB0014911 HMDB0014911_nmr_one_2347 https://hmdb.ca/metabolites/HMDB0014911#spectra ChEBI Etoposide http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4911 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking ETOPOSIDE https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C491 NCI Thesaurus Tree https://ncit.nci.nih.gov ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html ETOPOSIDE https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ETOPOSIDE Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking etoposide https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset Nature Chemical Biology https://pubchem.ncbi.nlm.nih.gov/substance/24769897 https://pubchem.ncbi.nlm.nih.gov/substance/117682510 Drugs and Lactation Database (LactMed) LICENSE https://www.nlm.nih.gov/copyright.html Etoposide https://www.ncbi.nlm.nih.gov/books/NBK500643/ EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ NITE-CMC Etoposide – FY2009 https://www.nite.go.jp/chem/english/ghs/09-mhlw-0225e.html FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking ETOPOSIDE https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory International Agency for Research on Cancer (IARC) https://publications.iarc.fr/Terms-Of-Use Etoposide https://monographs.iarc.who.int/list-of-classifications IARC Classification https://www.iarc.fr/ MassBank of North America (MoNA) LICENSE The content of the MoNA database is licensed under CC BY 4.0. https://mona.fiehnlab.ucdavis.edu/documentation/license Etoposide https://mona.fiehnlab.ucdavis.edu/spectra/browse?query NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Etoposide https://www.cancer.gov/about-cancer/treatment/drugs/etoposide NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html etoposide https://rxnav.nlm.nih.gov/id/rxnorm/4179 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/EVP PubChem https://pubchem.ncbi.nlm.nih.gov RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=42063394-737657571 https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=42063394-737744674 Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=42063394-737657571 https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=42063394-737744674 WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ WHO Model Lists of Essential Medicines https://www.who.int/about/who-we-are/publishing-policies/copyright Etoposide https://list.essentialmeds.org/medicines/88 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Etoposide https://www.wikidata.org/wiki/Q418817 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Etoposide https://www.ncbi.nlm.nih.gov/mesh/68005047 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antineoplastic Agents, Phytogenic https://www.ncbi.nlm.nih.gov/mesh/68000972 Topoisomerase II Inhibitors https://www.ncbi.nlm.nih.gov/mesh/68059005 KEGG https://www.kegg.jp/kegg/legal.html Therapeutic category of drugs in Japan http://www.genome.jp/kegg-bin/get_htext?br08301.keg USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drugs listed in the Japanese Pharmacopoeia http://www.genome.jp/kegg-bin/get_htext?br08311.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ PATENTSCOPE (WIPO) SID 388522486 https://pubchem.ncbi.nlm.nih.gov/substance/388522486 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More